What is EpiCypher?
EpiCypher operates at the forefront of epigenetics and chromatin biology, offering advanced tools and services to the scientific community. The company specializes in providing a comprehensive suite of assays, sophisticated bioinformatics platforms, and bespoke development services designed to accelerate chromatin research. By fostering collaborations with academic institutions, industry partners, and clinical trial organizations, EpiCypher is dedicated to driving innovation and advancing human health through cutting-edge scientific endeavors. Their commitment to excellence and client success underpins their continuous efforts to push the boundaries of epigenetic understanding.
How much funding has EpiCypher raised?
EpiCypher has raised a total of $992K across 2 funding rounds:
Debt
$350K
Debt
$642K
Debt (2020): $350K with participation from PPP
Debt (2021): $642K led by PPP
Key Investors in EpiCypher
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for EpiCypher?
The recent major strategic investment suggests EpiCypher is entering a phase of accelerated scaling and market penetration. This capital infusion is expected to fuel further research and development, potentially leading to the expansion of their service offerings and the enhancement of their existing product lines. Strategic partnerships are likely to deepen, enabling EpiCypher to tackle more complex research challenges and solidify its position as a leader in the epigenetics and chromatin biology landscape. The company's focus on scientific advancement and its collaborative approach position it for sustained impact in improving human health.
See full EpiCypher company page
